RxDoctor Payments Data

Luz Cano, MD

Neurology · Newport Beach, CANPI 1619993698

Payments from drug & device makers

$28,511in general payments, 2019–2025

Across 1,150 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$3K
  • Novartis$2K
  • Medtronic$1K
  • Amgen$1K
  • Pfizer$1K
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$230%
  • Travel & lodging$9393%
  • Food & beverage$27,48496%
  • Education$640%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)197$4,181
UCB, Inc.131$3,443
Novartis125$2,186
Medtronic(2 entities)13$1,374
Amgen(2 entities)43$1,353
Pfizer63$1,272
Novo Nordisk58$1,167
Neurocrine Biosciences, Inc.32$1,092
AstraZeneca(2 entities)26$1,056
Amneal Pharmaceuticals LLC35$965
Biogen40$956
Lilly USA, LLC34$856
Johnson & Johnson(2 entities)34$805
Takeda Pharmaceuticals U.S.A., Inc.36$694
Axsome Therapeutics, Inc.22$508
Eisai Inc.11$388
Teva Pharmaceuticals USA, Inc.24$378
Genentech USA, Inc.18$309
ANI Pharmaceuticals, Inc.14$309
CSL Behring10$307
Antares Pharma, Inc.8$259
Harmony Biosciences LLC7$242
Argenx US, Inc.7$242
TG Therapeutics, Inc.8$240
Biohaven Pharmaceutical Holding Company Ltd.10$228
Biohaven Pharmaceuticals, Inc.9$216
Supernus Pharmaceuticals, Inc.4$190
Akcea Therapeutics, Inc.3$176
Avanir Pharmaceuticals, Inc.3$169
Upsher-smith Laboratories LLC7$161
EMD Serono, Inc.6$158
Aimmune Therapeutics, Inc.4$157
Boston Scientific7$154
Octapharma USA, Inc.3$151
IBSA Pharma Inc.7$140
GE HealthCare6$138
Bristol Myers Squibb6$133
Currax Pharmaceuticals LLC7$119
Alnylam Pharmaceuticals Inc.4$104
Lundbeck LLC5$94
Mallinckrodt Hospital Products Inc.4$89
Cleerly, Inc.2$88
Vanda Pharmaceuticals Inc.3$83
Mallinckrodt Enterprises LLC3$74
Inspire Medical Systems, Inc.2$70
Catalyst Pharmaceuticals, Inc.2$65
Impel Pharmaceuticals Inc.3$63
Assertio Therapeutics, Inc.3$63
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$58
Strongbridge US Inc.3$53
Xeris Pharmaceuticals, Inc.2$52
Bausch Health US, LLC3$52
Neuropace, Inc.2$50
MDD US Operations, LLC2$49
Genentech, Inc.2$48
Alfasigma USA, Inc.2$47
Tanabe Pharma America, Inc.2$45
Exact Sciences2$44
Arbor Pharmaceuticals, Inc.2$38
Adamas Pharmaceuticals, Inc.2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,511 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$177,838
Medicare patients
119
Services billed
700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide108$112,619
OzempicSemaglutide103$104,838
Repatha SureclickEvolocumab95$57,359
EliquisApixaban15$23,872
Praluent PenAlirocumab23$15,795
JardianceEmpagliflozin14$14,457
QuliptaAtogepant13$14,284
Emgality PenGalcanezumab-Gnlm18$12,589
Cyclosporine15$11,088
MyrbetriqMirabegron13$6,024
Memantine Hcl ErMemantine Hcl24$4,869
Azelaic Acid16$4,769
Travoprost13$4,104
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$3,134
Vilazodone Hcl16$2,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$856$112,619108 claims
Novo NordiskOzempic$1,167$104,838103 claims
PfizerEliquis$1,272$23,87215 claims
AbbVieQulipta$4,181$14,28413 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$965$79242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →